Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
|
By LabMedica International staff writers Posted on 31 Jul 2018 |

Image: The EasyRA high-speed benchtop analyzer (Photo courtesy of Carolina Liquid Chemistries).
Carolina Liquid Chemistries (Greensboro, NC, USA) promoted its EasyRA high-speed benchtop analyzer, its family of clinical chemistry analyzers, CLC800, CLC1600, CLC6410, and extensive menu of reagents at the 70th annual AACC Scientific Meeting & Clinical Lab Expo held from July 31 – August 2. The company also introduced the Maglumi 2000 immunoassay analyzer at the event held in Chicago, USA.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Carolina Liquid Chemistries offers an extensive clinical chemistry reagent menu, ranging from general chemistries to urine drug screens and cardiovascular tests such as LpPLA2. The company markets a complete line of cost effective chemistry analyzers and service options for clinical laboratories of all sizes.
At AACC 2018, Carolina Liquid Chemistries highlighted the EasyRA, a high-speed benchtop clinical chemistry analyzer that accommodates the diverse needs of small to medium sized laboratories. Its all-in-one system allows laboratories to perform moderately complex urine drug screens and general chemistry tests on a single analyzer. With 300 tests per hour (480 with integrated ISE), an intuitive user interface, and the ability to analyze STAT samples in less than eight minutes, it is well suited for a variety of clinical laboratories located in satellite facilities, physician offices, pain management clinics, and urgent care centers.
In addition to the EasyRA, the company highlighted its family of floor model chemistry analyzers, the CLC800, CLC1600, and the CLC6410, which offer high throughputs from 400 to 900 to 3,200 photometric tests per hour. The FDA-cleared clinical chemistry analyzers are excellent for clinical laboratories located in mid-size group practices, large clinics, small and large hospitals or reference laboratories of all sizes.
Carolina Liquid Chemistries also highlighted its extensive reagent menu of products for both general chemistry and urine drug testing. This included 40 general chemistries, 27 urine drug screens, 15 immunochemistries and 24 special chemistries, including vLp-PLA2 (PLAC), Vitamin D (2-part), Procalcitonin (PCT) and Human Κ/λ Free Light Chain. Also on display at the event was the Maglumi 2000 immunoassay analyzer.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
- Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more





.jpg)



